论文部分内容阅读
目的探讨三氧化二砷(As2O3)联合支气管动脉灌注化疗(BAl)与单纯BAI治疗中晚期原发性肺癌的疗效、生存率、毒副反应差异。方法76例中晚期肺癌均经病理学确诊。研究组39例,BAI同时经导管给予As2O310mg治疗。对照组37例,单纯行BAI治疗。结果术后两组患者临床症状大部分缓解,咯血、咳嗽、胸痛好转,情况无差异(P>0.05);研究组中胸水吸收消退程度优于对照组,其中2例完全吸收,消退时间为3个月和5个月。毒副反应均轻微,无统计学意义(P>0.05)。研究组近期有效率为75%,对照组59%(P>0.05)。1年、2年、3年生存率两组分别为51%、10.3%、3%和38%、5%、0(P<0.05)。两组均未出现脊髓损伤、死亡等严重并发症。结论两种疗法的近期疗效、毒副反应相当;但AsO联合BAI能提高中晚期肺癌患者生存率,改善预后。
Objective To investigate the efficacy, survival rate and toxicity of arsenic trioxide combined with bronchial artery infusion chemotherapy (BAl) and BAI alone in the treatment of advanced primary lung cancer. Methods 76 cases of advanced lung cancer were pathologically confirmed. In the study group, 39 cases were treated by BAI with As2O310mg. Control group, 37 cases, simple BAI treatment. Results The clinical symptoms of the two groups were mostly relieved and hemoptysis, cough and chest pain were improved (P> 0.05). The extent of pleural effusion absorption in the study group was better than that of the control group, of which 2 cases were completely absorbed and the regression time was 3 Months and 5 months. Toxicity were mild, not statistically significant (P> 0.05). The study group, the effective rate was 75%, 59% of the control group (P> 0.05). The 1-, 2-, 3- year survival rates were 51%, 10.3%, 3% and 38%, 5%, 0 (P <0.05) respectively. No serious complications such as spinal cord injury and death occurred in both groups. Conclusions The short-term curative effect of the two therapies is similar to that of side effects. However, AsO plus BAI can improve the survival rate and improve the prognosis of patients with advanced lung cancer.